BPC-157 vs Pentadecapeptide (BPC Analog)
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
Nature's tissue-healing peptide from gastric juice—a 15-amino acid powerhouse for recovery
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
BPC-157
250–500 mcg
Pentadecapeptide (BPC Analog)
200–500 mcg
Frequency
BPC-157
Once daily
Pentadecapeptide (BPC Analog)
Once daily
Administration
BPC-157
Subcutaneous injection
Pentadecapeptide (BPC Analog)
Intramuscular injection
Cycle length
BPC-157
4-6 weeks
Pentadecapeptide (BPC Analog)
Ongoing/indefinite
Onset speed
BPC-157
Moderate (1-2 weeks)
Pentadecapeptide (BPC Analog)
Moderate (1-2 weeks)
Evidence level
BPC-157
Strong preclinical (extensive animal studies)
Pentadecapeptide (BPC Analog)
Moderate human trials (Phase 1-2)
Benefit ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Tissue Repair & Recovery
Angiogenesis (Blood Vessel Formation)
Anti-Inflammatory Effects
Compound specifications
BPC-157
Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0
Pentadecapeptide (BPC Analog)
Molecular formula
C62H98N16O22
Molecular weight
1419.5 g/mol
Half-life
Not precisely established in humans; likely hours to days depending on tissue depot
Bioavailability
Significantly improved with parenteral administration (injection); poor with oral route
CAS number
Not assigned (research compound)
Dosing compared
BPC-157
Subcutaneous
250 mcg
Once daily · 1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily · 4-6 weeks
Commonly used range for tissue and tendon recovery in research practice [1][3].
500 mcg
Twice daily · 6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Pentadecapeptide (BPC Analog)
Subcutaneous
250 mcg
Once daily · 1-2 weeks
A common starting amount in research practice, often injected near the injured area. As a BPC-157 analog it follows the same documented practice; no human trials exist, so doses come from animal studies (reference ~10 mcg/kg) and community practice [1][2].
200-500 mcg
Once or twice daily · 4-6 weeks
Commonly used range for tissue and tendon recovery in research practice, mirroring BPC-157 dosing [1][3].
500 mcg
Twice daily · 6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Best suited for
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]
Pentadecapeptide (BPC Analog)
Recovering from sports injuries or muscle strains
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on recovering from sports injuries or muscle strains. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting post-surgery tissue repair
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on supporting post-surgery tissue repair. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Accelerating tendon and ligament healing
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on accelerating tendon and ligament healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving overall recovery speed
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on improving overall recovery speed. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Pentadecapeptide (BPC Analog)
Common
- Injection site irritation
- Headache
- Nausea
Uncommon
- Dizziness
- Mood or anxiety changes
Serious
- Allergic reaction
Safety & evidence
BPC-157
Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
- History of cancer
Pentadecapeptide (BPC Analog)
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
BPC-157 analogs show favorable safety in animal toxicity studies with LD50 >1000 mg/kg (oral, rats). No serious adverse events in limited clinical case reports; mild local injection site effects observed. Gastroprotective mechanism suggests low systemic toxicity; rapid hepatic metabolism limits systemic exposure. Preclinical studies show no mutagenicity, carcinogenicity, or teratogenicity; reproductive safety appears favorable.
Contraindications
- Active cancer or high cancer risk
- Pregnancy or breastfeeding
- Known hypersensitivity to peptides
Which is right for you?
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Choose Pentadecapeptide (BPC Analog) if...
- Recovering from sports injuries or muscle strains
- Supporting post-surgery tissue repair
- Accelerating tendon and ligament healing
- Improving overall recovery speed